Trending News

Map of China
#AstraZeneca #China #Investment #Obesity #Weight loss

AZ expands China operations, agrees obesity deal with CSPC

AstraZeneca has agreed a new strategic collaboration agreement with China’s CSPC Pharmaceuticals to develop multiple next-generation therapies for obesity and type 2 diabetes across eight programmes.   Under this agreement, the companies will initially progress four programmes, which utilise CSPC's AI-driven peptide drug discovery platform and its LiquidGel once-monthly dosing platform… Read More

#Business & Investment #News #Trending News

Neurons
#Amyotrophic lateral sclerosis (ALS) #MND #Neuroscience #NRG Therapeutics #Phase I trial

Disease-modifying treatment for ALS enters Phase I

The first participants have been dosed in the first-in-human Phase I clinical trial of NRG Therapeutics’ lead candidate NRG5051, which is being developed as a treatment for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) and Parkinson’s.   NRG5051 is a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial… Read More

#News #Trending News

#GlobalData #Investment #Pharmaceutical industry #Politics #Tariffs #UK #United States

Is US foreign policy uncertainty strengthening confidence in the UK?

The recent UK-US policy developments are reshaping global pharmaceutical investment and launch strategies, according to intelligence platform GlobalData.  In December 2025, the UK announced a landmark pharmaceuticals agreement with the US, granting UK-made medicines and medical technologies tariff-free access to the US market for at least three years.   Alongside this,… Read More

#Business & Investment #News #Trending News

Overweight man clutching his knee
#Arthritis #Eli Lilly #Monoclonal antibodies #Obesity #Phase III trial #Weight loss

Combination therapy moves the needle in arthritis and obesity

Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together have been shown to deliver superior efficacy in first-of-its-kind Phase IIIb trial for adults with active psoriatic arthritis (PsA) and obesity or who are overweight.  At 36 weeks, treatment with concomitant Taltz and Zepbound met the primary and all… Read More

#News #Trending News

NVIDIA office Paris
#Artificial intelligence (AI) #Collaboration #Drug discovery #Eli Lilly #JP Morgan Healthcare Conference #NVIDIA #Thermo Fisher Scientific

NVIDIA expands drug discovery platform, partners with Lilly

NVIDIA has announced a major expansion of NVIDIA BioNeMo, its open development platform for AI-driven biology and drug discovery, at the JP Morgan Healthcare Conference.  The platform has expanded to include:  New NVIDIA Clara open models, the RNAPro model for RNA structure prediction and the ReaSyn v2 model  BioNeMo Recipes… Read More

#Business & Investment #News #Trending News

Eye
#Advanced Therapies #FDA #Gene editing #Gene therapy #GenEditBio #Genetic diseases #Ophthalmology #Phase I trial

GenEditBio gets green light for in vivo genome-editing programme

The US Food and Drug Administration (FDA) has cleared GenEditBio to initiate Phase I/II CLARITY trial activities for its lead in vivo genome-editing programme GEB-101 for TGFBI corneal dystrophy.  The Phase 1/2 CLARITY trial will collect initial data on the safety, tolerability and efficacy of GEB-101 in corneal dystrophy patients… Read More

#News #Regulatory #Trending News

FDA
#FDA #GLP-1 #Novo Nordisk #Obesity #Weight loss

FDA approves first oral GLP-1 for weight management

The US Food and Drug Administration (FDA) has approved the Wegovy pill (once-daily oral semaglutide 25mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events.  The Wegovy pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy… Read More

#News #Regulatory #Trending News

European Commission
#EU #European Commission #European Medicines Agency #Personalised medicine #Regulatory

New agreement to reshape EU pharmaceutical legislation

A landmark political agreement has been reached by the European Commission, the European Parliament and the Council of the European Union on a comprehensive reform of the EU pharmaceutical legislation. The agreement represents the most significant overhaul of the regulatory framework in over two decades and is described as a… Read More

#News #Regulatory #Trending News

UK and US flags
#ABPI #National Institute for Health and Care Excellence (NICE) #Pharmaceutical industry #UK government

UK-US pharmaceuticals deal supports UK life sciences

A trade deal has been agreed between the UK and the US, which the governments says will secure and expand access to drugs, safeguard the medicines supply chain, and “drive crucial investment while supporting UK patients and industries”.   The deal – part of the UK-US Economic Prosperity Deal – sees the… Read More

#Business & Investment #News #Trending News

#Alzheimer's #GLP-1 #Neurodegenerative disorders #Novo Nordisk #Obesity

Semaglutide shows no benefit in Alzheimer’s disease

Novo Nordisk has revealed that its Phase III trials of semaglutide (the active ingredient in Ozempic and Wegovy) did not demonstrate a statistically significant reduction in Alzheimer's disease progression.  The top-line results from the two-year primary analysis of evoke and evoke+ Phase III trials in early-stage symptomatic Alzheimer’s disease were… Read More

#Business & Investment #News #Trending News

FDA headquarters
#Cell and gene therapy #FDA #Personalised medicine #Regulatory

FDA introduces new pathway for personalised medicines

The US Food and Drug Administration (FDA) has laid out the process and requirements of its novel plausible mechanism pathway for personalised medicine in a New England Journal of Medicine (NEJM) editorial by Commissioner Martin Makary and Deputy Vinay Prasad.  The editorial acknowledges that personalised therapies “challenge traditional models of… Read More

#News #Regulatory #Trending News

CRISPR gene editing
#Cardiovascular disease #Cholesterol #CRISPR #CRISPR Therapeutics #CRISPR-Cas9 #Phase I trial

In vivo CRISPR gene editing therapy lowers cholesterol

CRISPR Therapeutics has shared positive Phase I data from an ongoing clinical trial evaluating CTX310, an investigational, in vivo CRISPR/Cas9 gene-editing therapy targeting ANGPTL3.   A single-course treatment with CTX310 produced dose-dependent, durable reductions in circulating ANGPTL3 with a mean reduction from baseline of -73% (maximum… Read More

#News #Trending News

Metsera logo
#Mergers and acquisitions #Metsera #Novo Nordisk #Obesity #Pfizer #Weight loss

Pfizer finally wins bidding war to acquire Metsera

Following a week-long bidding war with Novo Nordisk, Pfizer has acquired obesity drug specialists Metsera for $10 billion, thanks to an intervention by the US Federal Trade Commission (FTC).  Metsera's Board of Directors unanimously recommended that Metsera stockholders approve the adoption of the amended Pfizer merger agreement and approve the… Read More

#Business & Investment #News #Trending News